Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

PARIS/PSP study group

doi:10.1016/j.ccell.2022.04.012

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

PARIS/PSP study group

Research output: Contribution to journal › Letter › peer-review

11 Scopus citations

Original language	English
Pages (from-to)	575-577
Number of pages	3
Journal	Cancer Cell
Volume	40
Issue number	6
DOIs	https://doi.org/10.1016/j.ccell.2022.04.012
State	Published - 13 Jun 2022

Access to Document

10.1016/j.ccell.2022.04.012

Cite this

@article{ea0b035cfa0f4e0da1bda003c039fae6,

title = "Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer",

author = "{PARIS/PSP study group} and Mack, {Philip C.} and Gomez, {Jorge E.} and Rodilla, {Ananda M.} and Carre{\~n}o, {Juan Manuel} and Hsu, {Chih Yuan} and Christian Rolfo and Noy Meshulami and Amy Moore and Brody, {Rachel I.} and King, {Jennifer C.} and Jacquelyn Treatman and Sooyun Lee and Ariel Raskin and Komal Srivastava and Gleason, {Charles R.} and {de Miguel-Perez}, Diego and D. Andre and H. Alshammary and {van Bakel}, H. and Berm{\'u}dez-Gonz{\'a}lez, {M. C.} and G. Cai and C. Cognigni and D. Floda and A. Firpo and G. Kleiner and N. Lyttle and W. Mendez and Mulder, {L. C.F.} and A. Oostenink and A. Rooker and A. Salimbangon and M. Saksena and L. Sominsky and Sordillo, {E. M.} and Johnstone Tcheou and Dominika Bielak and Rashmi Acharya and Gerber, {David E.} and Nicholas Rohs and Henschke, {Claudia I.} and Yankelevitz, {David F.} and Viviana Simon and Minna, {John D.} and Bunn, {Paul A.} and Adolfo Garc{\'i}a-Sastre and Florian Krammer and Yu Shyr and Hirsch, {Fred R.}",

note = "Funding Information: This work was supported by NCI SeroNET grant U54CA260560. The PARIS study was funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051. We would like to acknowledge support from The Mount Sinai Biorepository and Pathology CoRE, the CRIPT (Center for Research on Influenza Pathogenesis and Transmission), an NIAID-funded Center of Excellence for Influenza Research and Response (CEIRR, contract 75N93021C00014 to A.G.-S). We are very grateful to the patients and volunteers, without whom this study would not be possible. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines, which list F.K. as co-inventor. V.S. is also listed on the serological assay patent application as co-inventor, and A.G.-S. is listed on the NDV-based SARS-CoV-2 vaccine as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. F.K. has consulted for Merck and Pfizer (before 2020) and is currently consulting for Pfizer, 3rd Rock Ventures, Seqirus, and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. The Adolfo Garc{\'i}a-Sastre laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, and Merck, outside of the reported work. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, and Pfizer, outside of the reported work. J.D.M. acknowledges royalties from the NIH and UT Southwestern Medical Center for distribution of human cell lines. P.C.M. acknowledges honoraria from Amgen and Guardant Health. F.R.H. acknowledges scientific advisory board compensation from AstraZeneca/Daiichi, Genentech, Sanofi/Regeneron, Merck, Bristol-Myers Squibb, Novartis, Amgen, OncoCyte, Nectin Therapeutics, and Novocure. Institutional Research grants (University of Colorado): Amgen, Biodesix, Rain Therapeutics JCK: Advisory Boards: Boehringer Ingelheim, Bristol Myers Squibb, Invitae, Guardant. Institutional Research funding: Bristol Myers Squibb, Genentech, Novartis. C.R.: EMD Serono, AstraZeneca, Roche, Pfizer, Bristol Myer Squibb, Esai, BluePrint, CORE2, Sanofi-Regeneron, Mirati. J.E.G.: Advisory board for Bristol-Myer Squibb. Funding Information: This work was supported by NCI SeroNET grant U54CA260560 . The PARIS study was funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 . We would like to acknowledge support from The Mount Sinai Biorepository and Pathology CoRE , the CRIPT (Center for Research on Influenza Pathogenesis and Transmission) , an NIAID-funded Center of Excellence for Influenza Research and Response ( CEIRR , contract 75N93021C00014 to A.G.-S). We are very grateful to the patients and volunteers, without whom this study would not be possible. ",

year = "2022",

month = jun,

day = "13",

doi = "10.1016/j.ccell.2022.04.012",

language = "English",

volume = "40",

pages = "575--577",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

AU - PARIS/PSP study group

AU - Mack, Philip C.

AU - Gomez, Jorge E.

AU - Rodilla, Ananda M.

AU - Carreño, Juan Manuel

AU - Hsu, Chih Yuan

AU - Rolfo, Christian

AU - Meshulami, Noy

AU - Moore, Amy

AU - Brody, Rachel I.

AU - King, Jennifer C.

AU - Treatman, Jacquelyn

AU - Lee, Sooyun

AU - Raskin, Ariel

AU - Srivastava, Komal

AU - Gleason, Charles R.

AU - de Miguel-Perez, Diego

AU - Andre, D.

AU - Alshammary, H.

AU - van Bakel, H.

AU - Bermúdez-González, M. C.

AU - Cai, G.

AU - Cognigni, C.

AU - Floda, D.

AU - Firpo, A.

AU - Kleiner, G.

AU - Lyttle, N.

AU - Mendez, W.

AU - Mulder, L. C.F.

AU - Oostenink, A.

AU - Rooker, A.

AU - Salimbangon, A.

AU - Saksena, M.

AU - Sominsky, L.

AU - Sordillo, E. M.

AU - Tcheou, Johnstone

AU - Bielak, Dominika

AU - Acharya, Rashmi

AU - Gerber, David E.

AU - Rohs, Nicholas

AU - Henschke, Claudia I.

AU - Yankelevitz, David F.

AU - Simon, Viviana

AU - Minna, John D.

AU - Bunn, Paul A.

AU - García-Sastre, Adolfo

AU - Krammer, Florian

AU - Shyr, Yu

AU - Hirsch, Fred R.

N1 - Funding Information: This work was supported by NCI SeroNET grant U54CA260560. The PARIS study was funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051. We would like to acknowledge support from The Mount Sinai Biorepository and Pathology CoRE, the CRIPT (Center for Research on Influenza Pathogenesis and Transmission), an NIAID-funded Center of Excellence for Influenza Research and Response (CEIRR, contract 75N93021C00014 to A.G.-S). We are very grateful to the patients and volunteers, without whom this study would not be possible. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines, which list F.K. as co-inventor. V.S. is also listed on the serological assay patent application as co-inventor, and A.G.-S. is listed on the NDV-based SARS-CoV-2 vaccine as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. F.K. has consulted for Merck and Pfizer (before 2020) and is currently consulting for Pfizer, 3rd Rock Ventures, Seqirus, and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. The Adolfo García-Sastre laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, and Merck, outside of the reported work. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, and Pfizer, outside of the reported work. J.D.M. acknowledges royalties from the NIH and UT Southwestern Medical Center for distribution of human cell lines. P.C.M. acknowledges honoraria from Amgen and Guardant Health. F.R.H. acknowledges scientific advisory board compensation from AstraZeneca/Daiichi, Genentech, Sanofi/Regeneron, Merck, Bristol-Myers Squibb, Novartis, Amgen, OncoCyte, Nectin Therapeutics, and Novocure. Institutional Research grants (University of Colorado): Amgen, Biodesix, Rain Therapeutics JCK: Advisory Boards: Boehringer Ingelheim, Bristol Myers Squibb, Invitae, Guardant. Institutional Research funding: Bristol Myers Squibb, Genentech, Novartis. C.R.: EMD Serono, AstraZeneca, Roche, Pfizer, Bristol Myer Squibb, Esai, BluePrint, CORE2, Sanofi-Regeneron, Mirati. J.E.G.: Advisory board for Bristol-Myer Squibb. Funding Information: This work was supported by NCI SeroNET grant U54CA260560 . The PARIS study was funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 . We would like to acknowledge support from The Mount Sinai Biorepository and Pathology CoRE , the CRIPT (Center for Research on Influenza Pathogenesis and Transmission) , an NIAID-funded Center of Excellence for Influenza Research and Response ( CEIRR , contract 75N93021C00014 to A.G.-S). We are very grateful to the patients and volunteers, without whom this study would not be possible.

PY - 2022/6/13

Y1 - 2022/6/13

UR - http://www.scopus.com/inward/record.url?scp=85132586487&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2022.04.012

DO - 10.1016/j.ccell.2022.04.012

M3 - Letter

AN - SCOPUS:85132586487

SN - 1535-6108

VL - 40

SP - 575

EP - 577

JO - Cancer Cell

JF - Cancer Cell

IS - 6

ER -